fbpx

AI-powered OCT workflow with Altris AI

Guidance on AI-enhanced OCT workflow for ophthalmologists
background
maria

Maria Znamenska, Retina Expert, PhD Ophthalmology, Altris AI Medical Director

How can an ophthalmologist use AI for OCT scan analysis?

My name is Maria Znamenska. I am an ophthalmologist with a PhD in ophthalmology and the Medical Director of Altris AI. I have been practicing and teaching OCT for more than 16 years. I want to show you how Artificial Intelligence can be used for OCT analysis with real OCT scans with AMD (drusen), DR, and GA retina pathologies.

OCT is an indispensable tool for any modern ophthalmology specialist. AI-powered OCT workflow provides a second opinion on complex OCT scans, allows the detection of early or minor biomarkers and pathologies, and assists in tracking the progression of biomarkers quantitatively, making the work of ophthalmologists faster and more accurate. 

Navigating dAMD (Drusen), dAMD (GA), DR

Altris AI AI for OCT Workflow for Ophthalmologists

14 Days Free Trial to those who are ready to empower and eye clinic with AI

Free Trial
background

AI for OCT Workflow for ophthalmologists

  • Working with ocular pathologies detected by Altris AI

    When you come across a pathological scan that you want to explore in detail, you go to the AI Pathologies Detection Module. Inside this module, AI analyzes the scan for the presence of 70+ biomarkers and retina pathologies.The system highlights each of them in color.

  • Working with ocular pathologies with precise biomarkers measurement

    Each biomarker can be measured in terms of segmentation volume and area automatically with excellent precision.

  • Pathology progression analysis through Altris AI
    Green magnifying glass icon

    Progression analysis allows adding examinations from different visits in historical order and seeing the transformation of biomarkers and retina pathologies.

  • Early glaucoma risk assessment with Altris AI

    Early glaucoma risk assessment is based on the analysis of GCC asymmetry and informs about high risk of early glaucoma.

  • Customizable OCT reports
    Examination results can be saved or printed as a customizable report, detailing basic information, severity detection, layer segmentation, specific pathologies, biomarker tracking, and more.

Choose a patient's journey

AI-powered OCT workflow for the patient with DR

Diabetic retinopathy (DR) is a microvascular disorder caused by vision-threatening damage to the retina, a long-term sequela of diabetes mellitus.

  • Biomarker of Diabetic Retinopathy, Hard Exudates
    Green magnifying glass icon

    Hard exudates. They are composed of lipid and proteinaceous material, such as fibrinogen and albumin that leak from the impaired blood–retinal barrier.

  • Biomarker of Diabetic Retinopathy, Diffuse Edema
    Green magnifying glass icon

    Diffuse Edema. It is a thickened area of lower reflectivity in the outer retina but specifically without cystoid spaces.

  • Biomarker of Diabetic Retinopathy, Intraretinal hyperreflective foci
    Green magnifying glass icon

    Intraretinal hyprereflective foci are typically dot-like or round, regular lesions seen in all the retinal layers and choroid.

  • Biomarker of Diabetic Retinopathy, Intraretinal cystoid fluid
    Green magnifying glass icon

    Intraretinal cystoid fluid. The fluid inside the retina which is accumulated as cystic cavities.

AI-powered OCT workflow for the patient with dAMD (Drusen)

The presence of a large number of larger drusen is an early sign of dry age-related macular degeneration (AMD).

  • Biomarker of dAMD, Soft drusen
    Green magnifying glass icon

    Soft drusen are larger, cluster together, and have edges that are not as clearly defined.

  • Biomarker of dAMD, RPE disruption
    Green magnifying glass icon

    RPE Disruption is the disruption of the Retinal Pigment Epithelium layer

  • Biomarker of dAMD, Cuticular drusen
    Green magnifying glass icon

    Cuticular drusen are small with steep sides and contain dense hyalinized contents that are identical to small, hard drusen.

  • Biomarker of dAMD, Hard drusen
    Green magnifying glass icon

    Hard drusen are small, and indicate lower risk of future vision loss.

  • Biomarker of dAMD, Ellipsoid zone disruption
    Green magnifying glass icon

    The ellipsoid zone is a hyperreflective outer retinal band just posterior to the external limiting membrane. Its integrity is correlating with visual acuity and other aspects of retinal function.

AI-powered OCT workflow for the patient with dAMD (GA)

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea.

  • Biomarker of dAMD-Geographic Atrophy, Hypertransmission
    Green magnifying glass icon

    Hypertransmission can be one of the biomarkers of GA.

  • Biomarker of dAMD-Geographic Atrophy, Hard drusen
    Green magnifying glass icon

    Hard drusen are small, and indicate lower risk of future vision loss.

  • Biomarker of dAMD-Geographic Atrophy, Soft drusen
    Green magnifying glass icon

    Soft drusen are larger, cluster together, and have edges that are not as clearly defined.

  • Biomarker of dAMD-Geographic Atrophy, Ellipsoid zone disruption
    Green magnifying glass icon

    Ellipsoid zone disruption is a hyperreflective outer retinal band just posterior to the external limiting membrane. Its integrity is correlating with visual acuity and other aspects of retinal function.

  • Biomarker of dAMD-Geographic Atrophy, Neurosensory retina atrophy
    Green magnifying glass icon

    Neurosensory retina atrophy – the atrophy of the inner layer.

  • Biomarker of dAMD-Geographic Atrophy, RPE atrophy
    Green magnifying glass icon

    RPE Atrophy – the atrophy of Retinal Pigment Epithelium layer.

  • Biomarker of dAMD-Geographic Atrophy, RPE disruption
    Green magnifying glass icon

    RPE Disruption – the disruption of the Retinal Pigment Epithelium layer.

nAMD(CNV)

  • Biomarker of NAMD(CNV), Ellipsoid zone disruption
    Green magnifying glass icon

    Ellipsoid Zone Disruption is a hyperreflective outer retinal band just posterior to the external limiting membrane. Its integrity is correlating with visual acuity and other aspects of retinal function.

  • Biomarker of NAMD(CNV), Posterior hyaloid membrane detachment
    Green magnifying glass icon

    Posterior Hyaloid Membrane Detachment occurs when the retinal layer and vitreous body/posterior hyaloid membrane dissociate, with an intervening fluid collection forming in the subhyaloid space.

  • Biomarker of NAMD(CNV), Subretinal hyperreflective material
    Green magnifying glass icon

    SHRM is a morphologic component seen as hyperreflective material that is external to the retina and internal to the retinal pigment epithelium (RPE).

  • Biomarker of NAMD(CNV), Diffuse edema
    Green magnifying glass icon

    Diffuse Edema is a thickened area of lower reflectivity in the outer retina but specifically without cystoid spaces.

  • Biomarker of NAMD(CNV), Fibrovascular RPE detachment
    Green magnifying glass icon

    Fibrovascular RPE detachment. Delamination of the pigment epithelium of the retina is caused by the presence of newly formed vessels (fibrovascular membrane) under the RPE.

  • Biomarker of NAMD(CNV), Subretinal fluid
    Green magnifying glass icon

    Subretinal Fluid corresponds to the accumulation of a clear or lipid-rich exudate (serous fluid) in the subretinal space.

  • Biomarker of NAMD(CNV), Double layer sign
    Green magnifying glass icon

    Double layer sign is a biomarker that is produced due to the shallow irregular pigment epithelial detachment.

  • Biomarker of NAMD(CNV), RPE disruption
    Green magnifying glass icon

    RPE Disruption is the disruption of the Retinal Pigment Epithelium layer.

maria
Maria Znamenska
MD, PhD Ophthalmology, Medical Director of Altris AI
With Altris AI the work of ophthalmologist becomes much more accurate and effective: AI accelerates and automates OCT screening so that ophthalmologists only work with pathological scans. More than that, Altris AI supports with diagnostic decision -making ensuring that minor/early/rare pathologies, including early glaucoma are not missed. Progression analysis module ensures that the ophthalmologist is tracing the progression of biomarkers quantitatively.
Early detection of glaucoma is challenging: the signs can be subtle, making them difficult to detect. Ganglion Cell Complex asymmetry analysis catergorises the risk of developing glaucoma. Glaucoma Early Risk Assessment Module can help decrease the number of false positive referrals and increase the standard of care by supporting the early diagnosis therefore, timely treatment will improve the patient's prognosis.

Book 14 Days of Free Trial

Book a Call
background

AI for OCT scan analysis offers every ophthalmologist a chance to unleash the full potential of this diagnostic tool.

OCT is the most effective method of retina diagnosis yet it requires years of learning and practice to truly master it. Altris AI ( AI for OCT) analysis becomes a solid and reliable diagnostic decision-making support tool for optometrists and dispensing opticians.

 

  • Altris AI detects 70+ pathologies and biomarkers
  • Altris AI assesses early risk of glaucoma
  • Altris AI enables quantitative progression analysis of biomarkers
  • Altris AI provides the chance to build customisable reports
While AI has the potential to assist ophthalmologists in various tasks, such as tracking pathology progression, early Glaucoma assessment risk measuring, and excluding nonpathological scans, it will never replace them. Ophthalmology requires a combination of deep medical expertise, patient interaction, and nuanced decision-making that’s challenging for AI to replicate entirely.